This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV efficacy findings in young women to young men based on the demonstration of similar immunogenicity and safety profiles. The primary hypothesis is that 9vHPV induces antibody responses at 4 weeks postdose 3 in heterosexual males that are non-inferior to antibody responses in young women.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine
Timeframe: Four weeks post vaccination 3 (Month 7)
Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card
Timeframe: Up to 5 days after any vaccination
Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)
Timeframe: Up to 5 days after any vaccination
Percentage of Participants With an Adverse Event
Timeframe: Up to Month 12
Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event
Timeframe: Up to Month 12